Combination Therapies Push Melanoma Field Forward
Source: OncLive, December 2017
Combination therapy continues to propel the treatment landscape for patients with melanoma in a positive direction, according to Michael A. Postow, MD, who adds that an area of interest is the combination of BRAF and MEK inhibitors with PD-1 therapy as well as combinations of LAG-3 inhibition plus PD-1 agents.
“The world is moving to 2- and 3-drug combinations and, if those show benefit in randomized studies, we will all be happy about that,” said Postow. “We need to keep in mind that we should be conservative with our thinking until we have the data to support what could be more expensive and toxic regimens.”
In an interview during the 2017 OncLive® State of the Science SummitTM on Melanoma, Postow, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the evolution of combination therapies for patients with melanoma.